Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The study aims to elucidate how 18F-Octreotide PET/CT or PET-MR can assist in accurate localization, treatment planning, prognostic predictions, and the selection of PRRT efficacy in neuroendocrine tumors. It also highlights important applications in lesion segmentation measurement, tumor grading, prognostic survival prediction, and genotype identification.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| 18F-AlF-NOTA-Octreotide PET-CT or PET-MR | Diagnostic Test | 18F-Octreotide PET/CT or PET/MR And enhanced CT or MR Imaging |
| Measure | Description | Time Frame |
|---|---|---|
| Diagnostic efficacy | Sensitivity, specificity, positive and negative predictive value of 18F-OC PET/CT and PET/MR Imaging in neuroendocrine neoplasms | through study completion, an average of 1.5 year |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Prognostic Value of Baseline 18F-OC PET for Progression-Free Survival (PFS) in High-Risk Patients | This measure evaluates the association between baseline 18F-OC PET parameters (e.g., SUVmax, SUVmean, metabolic tumor volume [MTV], total lesion glycolysis [TLG]) and progression-free survival (PFS) in high-risk neuroendocrine neoplasms patients. PFS will be defined as the time from diagnosis to disease progression or relapse, assessed using the Kaplan-Meier method and Cox proportional hazards model. |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Patients with a previous diagnosis of neuroendocrine tumors who are suspected of recurrence or metastasis.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Donghe Chen | Contact | 0571-87236432 | chendonghe@zju.edu.cn |
Not provided
Not provided
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_ICF | Yes | No | Yes | Study Protocol and Informed Consent Form | Nov 16, 2024 | Jul 28, 2025 | Prot_ICF_000.pdf |
Not provided
| ID | Term |
|---|---|
| D018358 | Neuroendocrine Tumors |
| ID | Term |
|---|---|
| D017599 | Neuroectodermal Tumors |
| D009373 | Neoplasms, Germ Cell and Embryonal |
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
Not provided
Not provided
Not provided
Not provided
Not provided
| through study completion, 3-4 years |
| D009380 | Neoplasms, Nerve Tissue |